Great Novel Therapeutics Biotech & Medicals (TPEX:7427)
34.00
+0.50 (1.49%)
At close: Feb 11, 2026
TPEX:7427 Revenue
Great Novel Therapeutics Biotech & Medicals had revenue of 623.00K TWD in the half year ending June 30, 2025, a decrease of -86.92%. This brings the company's revenue in the last twelve months to 1.78M, up 189.59% year-over-year. In the year 2024, Great Novel Therapeutics Biotech & Medicals had annual revenue of 1.69M, down -65.26%.
Revenue (ttm)
1.78M
Revenue Growth
+189.59%
P/S Ratio
807.91
Revenue / Employee
118.73K
Employees
15
Market Cap
1.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.69M | -3.17M | -65.26% |
| Dec 31, 2023 | 4.85M | 4.31M | 798.15% |
| Dec 31, 2022 | 540.00K | -90.00K | -14.29% |
| Dec 31, 2021 | 630.00K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genomics BioSci & Tech. | 607.89M |
| Meribank Biotech | 486.52M |
| GenMont Biotech Incorporation | 391.48M |
| Abnova (Taiwan) | 355.40M |
| GeneReach Biotechnology | 215.32M |
| NeoCore Technology | 190.10M |
| Lukas Biomedical | 180.32M |
| Holy Stone Healthcare | 47.51M |